AU2019329835B2 - Fascin binding compounds for spinogenesis - Google Patents

Fascin binding compounds for spinogenesis Download PDF

Info

Publication number
AU2019329835B2
AU2019329835B2 AU2019329835A AU2019329835A AU2019329835B2 AU 2019329835 B2 AU2019329835 B2 AU 2019329835B2 AU 2019329835 A AU2019329835 A AU 2019329835A AU 2019329835 A AU2019329835 A AU 2019329835A AU 2019329835 B2 AU2019329835 B2 AU 2019329835B2
Authority
AU
Australia
Prior art keywords
compound
formula
alkyl
group
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019329835A
Other languages
English (en)
Other versions
AU2019329835A1 (en
Inventor
Stella T. SARRAF
Vincent F. Simmon
Peter W. Vanderklish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spinogenix Inc
Original Assignee
Spinogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spinogenix Inc filed Critical Spinogenix Inc
Publication of AU2019329835A1 publication Critical patent/AU2019329835A1/en
Application granted granted Critical
Publication of AU2019329835B2 publication Critical patent/AU2019329835B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019329835A 2018-08-27 2019-08-27 Fascin binding compounds for spinogenesis Active AU2019329835B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862723381P 2018-08-27 2018-08-27
US62/723,381 2018-08-27
US201862726904P 2018-09-04 2018-09-04
US62/726,904 2018-09-04
US201862785435P 2018-12-27 2018-12-27
US62/785,435 2018-12-27
PCT/US2019/048408 WO2020046991A1 (en) 2018-08-27 2019-08-27 Fascin binding compounds for spinogenesis

Publications (2)

Publication Number Publication Date
AU2019329835A1 AU2019329835A1 (en) 2021-04-15
AU2019329835B2 true AU2019329835B2 (en) 2025-05-29

Family

ID=69644570

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019329835A Active AU2019329835B2 (en) 2018-08-27 2019-08-27 Fascin binding compounds for spinogenesis

Country Status (7)

Country Link
US (2) US20210330646A1 (enExample)
EP (1) EP3843846A4 (enExample)
JP (2) JP7583710B2 (enExample)
CN (1) CN112912141B (enExample)
AU (1) AU2019329835B2 (enExample)
CA (1) CA3110877A1 (enExample)
WO (1) WO2020046991A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3071525A1 (en) 2017-08-02 2019-02-07 Spinogenix, Inc. Benzothiazole and related compounds
ES3032326T3 (en) 2019-01-31 2025-07-17 Spinogenix Inc Solid forms of a promoter of spinogenesis
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
JP2024507224A (ja) * 2021-02-22 2024-02-16 スピノジェニックス， インコーポレイテッド 脊髄傷害または損傷を処置する方法
US20240180920A1 (en) * 2021-03-23 2024-06-06 Spinogenix, Inc. Certain fascin binding compounds for spinogenesis
AU2024244089A1 (en) * 2023-04-03 2025-10-30 Spinogenix, Inc. Methods of dosing spinogenic compounds
CN121773104A (zh) * 2023-06-30 2026-03-31 北京双鹤润创科技有限公司 肌成束蛋白抑制剂
WO2025184576A1 (en) * 2024-02-29 2025-09-04 Spinogenix, Inc. Methods for prevention and treatment of depression
WO2026050308A1 (en) * 2024-08-26 2026-03-05 Spinogenix, Inc. Benzothiazole compound for treating or preventing diabetes
WO2026050303A1 (en) * 2024-08-26 2026-03-05 Spinogenix, Inc. Methods of treating ophthalmic diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037411A1 (en) * 2011-09-14 2013-03-21 Proximagen Limited New enzyme inhibitor compounds
WO2014031732A2 (en) * 2012-08-22 2014-02-27 Cornell University Methods for inhibiting fascin
WO2015127125A1 (en) * 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
WO2019028164A1 (en) * 2017-08-02 2019-02-07 Spinogenix, Inc. BENZOTHIAZOLES AND RELATED COMPOUNDS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
AU2012239977B9 (en) 2011-04-07 2016-11-17 Sloan-Kettering Institute For Cancer Research Migrastatins and uses thereof
WO2013013240A2 (en) * 2011-07-21 2013-01-24 Theracrine, Inc. Macrocyclic compounds and related compositons and methods of use
CA3010445A1 (en) * 2016-01-05 2017-07-13 The Regents Of The University Of California Benzothiazole amphiphiles
TWI586367B (zh) 2016-03-28 2017-06-11 蔡懷楨 磷酸甘油酯激酶增加神經突生長及／或治療神經性疾病的用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037411A1 (en) * 2011-09-14 2013-03-21 Proximagen Limited New enzyme inhibitor compounds
WO2014031732A2 (en) * 2012-08-22 2014-02-27 Cornell University Methods for inhibiting fascin
WO2015127125A1 (en) * 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
WO2019028164A1 (en) * 2017-08-02 2019-02-07 Spinogenix, Inc. BENZOTHIAZOLES AND RELATED COMPOUNDS

Also Published As

Publication number Publication date
CN112912141B (zh) 2026-03-31
CA3110877A1 (en) 2020-03-05
EP3843846A4 (en) 2022-09-07
US20210330646A1 (en) 2021-10-28
JP7583710B2 (ja) 2024-11-14
WO2020046991A1 (en) 2020-03-05
US20240423962A1 (en) 2024-12-26
CN112912141A (zh) 2021-06-04
EP3843846A1 (en) 2021-07-07
JP2025016676A (ja) 2025-02-04
AU2019329835A1 (en) 2021-04-15
JP2021535159A (ja) 2021-12-16

Similar Documents

Publication Publication Date Title
US20240423962A1 (en) Fascin binding compounds for spinogenesis
JP7212781B2 (ja) 神経保護剤と組み合わせたｓａｒｍ１の阻害剤
US12486287B2 (en) Solid forms of a promoter of spinogenesis
JP2022058369A (ja) アルツハイマー病治療方法
US20130273557A1 (en) Compounds and methods of modulating mitochondrial bioenergetic efficiency through an interaction with atp synthase (complex v) and its subunits
CN112601516A (zh) 治疗与s1p1受体相关的病况的方法
JP2025165957A (ja) ブルトン型チロシンキナーゼ阻害剤を使用したシェーグレン症候群を処置する方法
WO2006055970A2 (en) Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
CN101808646A (zh) 用于改善帕金森氏病的运动并发症或精神症状的药剂
JP2023505063A (ja) トレフォイル因子ファミリーメンバー２モジュレーターによる老化関連障害処置のための方法および組成物
CN102365269A (zh) 用于治疗认知缺损的新药物
CA3128280C (en) Solid forms of a promoter of spinogenesis
HK40131867A (en) Solid forms of a promoter of spinogenesis
WO2025184576A1 (en) Methods for prevention and treatment of depression
HK40063672A (en) Solid forms of a promoter of spinogenesis
HK40063672B (en) Solid forms of a promoter of spinogenesis
US20240180920A1 (en) Certain fascin binding compounds for spinogenesis
AU2024244089A1 (en) Methods of dosing spinogenic compounds
WO2022246930A1 (zh) 靶向pdcd4的配体小分子在制备抗抑郁药物中的应用
JP2011520905A (ja) 向知性剤としてのムスカリンアゴニスト

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)